Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation

NCT03756922 is registered in ClinicalTrials.gov with Flatley Discovery Lab LLC as lead sponsor.

NCT NCT03756922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03756922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation
Lead sponsor
Flatley Discovery Lab LLC
Phase
Phase 1/2
Overall status
Suspended
Start date
November 27, 2018
Completion date
February 29, 2020
Enrollment
78 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis